Conatus Pharmaceuticals (NASDAQ:CNAT) had its target price cut by SunTrust Banks to $4.30 in a research note released on Thursday. They currently have a buy rating on the biotechnology company’s stock. SunTrust Banks also issued estimates for Conatus Pharmaceuticals’ FY2021 earnings at $2.25 EPS.
Several other equities analysts have also recently issued reports on the company. HC Wainwright dropped their price target on Conatus Pharmaceuticals from $17.00 to $15.00 and set a buy rating on the stock in a research report on Thursday. Oppenheimer set a $14.00 price target on Conatus Pharmaceuticals and gave the company a buy rating in a research report on Thursday. Zacks Investment Research cut Conatus Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, March 12th. ValuEngine upgraded Conatus Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, March 2nd. Finally, Roth Capital began coverage on Conatus Pharmaceuticals in a research report on Thursday, February 8th. They issued a buy rating and a $20.00 price target on the stock. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. Conatus Pharmaceuticals currently has a consensus rating of Buy and an average target price of $12.00.
Shares of CNAT stock opened at $4.03 on Thursday. Conatus Pharmaceuticals has a 52-week low of $3.85 and a 52-week high of $9.40. The company has a current ratio of 2.82, a quick ratio of 2.82 and a debt-to-equity ratio of 0.47.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. The firm had revenue of $8.80 million for the quarter, compared to analysts’ expectations of $9.60 million. Conatus Pharmaceuticals had a negative return on equity of 61.58% and a negative net margin of 49.17%. analysts anticipate that Conatus Pharmaceuticals will post -0.71 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MPM Asset Management LLC increased its position in Conatus Pharmaceuticals by 76.3% during the 4th quarter. MPM Asset Management LLC now owns 2,101,171 shares of the biotechnology company’s stock worth $9,707,000 after purchasing an additional 909,091 shares during the period. BlackRock Inc. increased its position in Conatus Pharmaceuticals by 6.2% during the 4th quarter. BlackRock Inc. now owns 1,593,395 shares of the biotechnology company’s stock worth $7,362,000 after purchasing an additional 93,015 shares during the period. Geode Capital Management LLC increased its position in Conatus Pharmaceuticals by 26.2% during the 4th quarter. Geode Capital Management LLC now owns 429,556 shares of the biotechnology company’s stock worth $1,983,000 after purchasing an additional 89,179 shares during the period. State Street Corp acquired a new position in Conatus Pharmaceuticals during the 2nd quarter worth approximately $2,092,000. Finally, TIAA CREF Investment Management LLC increased its position in Conatus Pharmaceuticals by 28.5% during the 4th quarter. TIAA CREF Investment Management LLC now owns 216,766 shares of the biotechnology company’s stock worth $1,001,000 after purchasing an additional 48,063 shares during the period. Institutional investors own 39.49% of the company’s stock.
WARNING: “Conatus Pharmaceuticals (CNAT) Price Target Cut to $4.30 by Analysts at SunTrust Banks” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/09/conatus-pharmaceuticals-cnat-price-target-cut-to-4-30-by-analysts-at-suntrust-banks.html.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.